James E. Hansen, MD, MS

• Antonio Omuro
• Charles Matouk
• Henry S. Park
• Jiangbing Zhou
• Kenneth B. Roberts
• Lynn D. Wilson
• Michael Girardi
• Peter M. Glazer
• Sacit Bulent Omay
• Sanjay Aneja
• Veronica Chiang

Immune System Diseases; Neoplasms; Therapeutics

• Selected-Lesion Stereotactic Radiosurgery in Treatment of Patients with Multiple Brain Metastases: A Single Institution Retrospective StudyMange A, Singh C, Theriault B, Hansen J, An Y, Aneja S, Chiang V. Selected-Lesion Stereotactic Radiosurgery in Treatment of Patients with Multiple Brain Metastases: A Single Institution Retrospective Study. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e135. DOI: 10.1016/j.ijrobp.2023.06.939.
• Cellular protection from H2O2 toxicity by Fv-Hsp70: protection via catalase and gamma-glutamyl-cysteine synthaseHino C, Chan G, Jordaan G, Chang S, Saunders J, Bashir M, Hansen J, Gera J, Weisbart R, Nishimura R. Cellular protection from H2O2 toxicity by Fv-Hsp70: protection via catalase and gamma-glutamyl-cysteine synthase. Cell Stress And Chaperones 2023, 28: 429-439. PMID: 37171750, PMCID: PMC10352194, DOI: 10.1007/s12192-023-01349-6.
• Inhibition of NETosis by a Nuclear-Penetrating Anti-DNA AutoantibodyChen X, Cuffari BJ, Dubljevic V, Shirali A, Zhou J, Campbell JA, Suits SC, O'Sullivan KM, Hansen JE. Inhibition of NETosis by a Nuclear-Penetrating Anti-DNA Autoantibody. ImmunoHorizons 2022, 6: 356-365. PMID: 35697479, DOI: 10.4049/immunohorizons.2100091.
• Defective Early B Cell Tolerance Checkpoints in Patients With Systemic Sclerosis Allow the Production of Self Antigen–Specific ClonesGlauzy S, Olson B, May CK, Parisi D, Massad C, Hansen JE, Ryu C, Herzog EL, Meffre E. Defective Early B Cell Tolerance Checkpoints in Patients With Systemic Sclerosis Allow the Production of Self Antigen–Specific Clones. Arthritis & Rheumatology 2021, 74: 307-317. PMID: 34279059, PMCID: PMC8766600, DOI: 10.1002/art.41927.
• Recognition and Management of Adverse Radiation EffectsCheok S, Hansen J, Chiang V. Recognition and Management of Adverse Radiation Effects. 2021, 391-404. DOI: 10.1201/9781003167464-36.
• ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibodyRattray Z, Deng G, Zhang S, Shirali A, May CK, Chen X, Cuffari BJ, Liu J, Zou P, Rattray N, Johnson CH, Dubljevic V, Campbell JA, Huttner A, Baehring JM, Zhou J, Hansen JE. ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody. JCI Insight 2021, 6: e145875. PMID: 34128837, PMCID: PMC8410084, DOI: 10.1172/jci.insight.145875.
• Chapter 48 Malignancies in systemic lupus erythematosusLadouceur A, Tissera H, Clarke A, Ramsey-Goldman R, Gordon C, Hansen J, Bernatsky S. Chapter 48 Malignancies in systemic lupus erythematosus. 2021, 461-467. DOI: 10.1016/b978-0-12-814551-7.00048-9.
• Impact of tissue heterogeneity correction on Gamma Knife stereotactic radiosurgery of acoustic neuromas.Peters GW, Tien CJ, Chiang V, Yu J, Hansen JE, Aneja S. Impact of tissue heterogeneity correction on Gamma Knife stereotactic radiosurgery of acoustic neuromas. Journal Of Radiosurgery And SBRT 2021, 7: 207-212. PMID: 33898084, PMCID: PMC8055239.
• NIMG-03. DEEP LEARNING SURVIVAL ANALYSIS FOR MULTIPLE BRAIN METASTASESChang E, Joel M, Chang H, Du J, Yu J, An Y, Hansen J, Omuro A, Chiang V, Aneja S. NIMG-03. DEEP LEARNING SURVIVAL ANALYSIS FOR MULTIPLE BRAIN METASTASES. Neuro-Oncology 2020, 22: ii147-ii147. PMCID: PMC7650895, DOI: 10.1093/neuonc/noaa215.616.
• Deep Learning Survival Analysis for Brain Metastases Treated with Stereotactic RadiosurgeryChang E, Joel M, Chang H, Du J, Yu J, An Y, Hansen J, Omuro A, Chiang V, Aneja S. Deep Learning Survival Analysis for Brain Metastases Treated with Stereotactic Radiosurgery. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: s164-s165. DOI: 10.1016/j.ijrobp.2020.07.932.
• Stereotactic Radiosurgery for Pediatric Arteriovenous Malformations: A Case Series Reflecting One Institution’s Experience With TreatmentChoi R, An Y, Aneja S, Bindra R, Bond J, Chiang V, Hansen J, Hebert R, Matouk C, Yu J. Stereotactic Radiosurgery for Pediatric Arteriovenous Malformations: A Case Series Reflecting One Institution’s Experience With Treatment. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e244. DOI: 10.1016/j.ijrobp.2020.07.589.
• LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapyChen Y, Jiang T, Zhang H, Gou X, Han C, Wang J, Chen AT, Ma J, Liu J, Chen Z, Jing X, Lei H, Wang Z, Bao Y, Baqri M, Zhu Y, Bindra RS, Hansen JE, Dou J, Huang C, Zhou J. LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy. Nature Cell Biology 2020, 22: 1276-1285. PMID: 33005030, PMCID: PMC7962994, DOI: 10.1038/s41556-020-00586-6.
• 64. AN ENT2-DEPENDENT, CELL-PENETRATING, AND DNA-DAMAGING LUPUS AUTOANTIBODY CROSSES THE BLOOD-BRAIN BARRIER TO TARGET BRAIN TUMORSRattray Z, Deng G, Zhang S, Shirali A, May C, Liu J, Zou P, Cuffari B, Rattray N, Johnson C, Dubljevic V, Campbell J, Huttner A, Baehring J, Zhou J, Hansen J. 64. AN ENT2-DEPENDENT, CELL-PENETRATING, AND DNA-DAMAGING LUPUS AUTOANTIBODY CROSSES THE BLOOD-BRAIN BARRIER TO TARGET BRAIN TUMORS. Neuro-Oncology Advances 2020, 2: ii13-ii13. PMCID: PMC7401412, DOI: 10.1093/noajnl/vdaa073.051.
• Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapy.Miccio JA, Barsky A, Gao S, Verma V, Noticewala SS, Jairam V, Johnson SB, Yu JB, Hansen JE, Aneja S, An Y, Decker RH, Bulent Omay S, Li J, Kurtz GA, Alonso-Basanta M, Lee JYK, Chiang VL, Park HS. Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapy. Journal Of Radiosurgery And SBRT 2020, 7: 19-27. PMID: 32802575, PMCID: PMC7406345.
• Impact of Tissue Heterogeneity Correction on Stereotactic Radiosurgery of Acoustic NeuromasWelch G, Tien C, Chiang V, Yu J, Hansen J, Aneja S. Impact of Tissue Heterogeneity Correction on Stereotactic Radiosurgery of Acoustic Neuromas. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e785. DOI: 10.1016/j.ijrobp.2019.06.749.
• Upfront Stereotactic Radiosurgery in the Treatment of Brain Metastasis from Small Cell Lung CancerMiccio J, Johnson S, Jairam V, Yu J, Hansen J, Aneja S, An Y, Decker R, Omay S, Chiang V, Park H. Upfront Stereotactic Radiosurgery in the Treatment of Brain Metastasis from Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e81-e82. DOI: 10.1016/j.ijrobp.2019.06.2348.
• BSCI-04. TARGETING TRIPLE-NEGATIVE BREAST CANCER BRAIN METASTASES WITH A RE-ENGINEERED LUPUS AUTOANTIBODYZhang S, May C, Shirali A, Dubljevic V, Campbell J, Zhou J, Hansen J. BSCI-04. TARGETING TRIPLE-NEGATIVE BREAST CANCER BRAIN METASTASES WITH A RE-ENGINEERED LUPUS AUTOANTIBODY. Neuro-Oncology Advances 2019, 1: i1-i2. PMCID: PMC7213175, DOI: 10.1093/noajnl/vdz014.003.
• Results of a pilot/phase II study of gamma knife radiosurgery for brain metastases and implications for future prospective clinical trialsYu J, Singh C, Bindra R, Contessa J, Husain Z, Hansen J, Park H, Roberts K, Bond J, Tien C, Guo F, Colaco R, Housri N, Magnuson W, Mahajan A, Omay S, Chiang V. Results of a pilot/phase II study of gamma knife radiosurgery for brain metastases and implications for future prospective clinical trials. Journal Of Radiation Oncology 2019, 8: 39-46. DOI: 10.1007/s13566-018-0370-7.
• A Pilot/Phase II Study of Stereotactic Radiosurgery for Brain Metastases Using Rational Dose SelectionYu J, Singh C, Bindra R, Contessa J, Husain Z, Hansen J, Park H, Roberts K, Bond J, Tien C, Guo F, Colaco R, Housri N, Magnuson W, Omay B, Chiang V. A Pilot/Phase II Study of Stereotactic Radiosurgery for Brain Metastases Using Rational Dose Selection. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e372-e373. DOI: 10.1016/j.ijrobp.2018.07.1113.
• Incidence of Radiographically Occult Nodal Metastases in HPV-Driven Oropharyngeal Carcinoma: Implications for Reducing Elective Nodal CoverageKelly J, Loganadane G, Lee N, Kann B, Mahajan A, Hansen J, Belkacemi Y, Yarbrough W, Husain Z. Incidence of Radiographically Occult Nodal Metastases in HPV-Driven Oropharyngeal Carcinoma: Implications for Reducing Elective Nodal Coverage. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s197-s198. DOI: 10.1016/j.ijrobp.2018.07.095.
• Evolving National Practice Patterns of Hypofractionated Stereotactic Radiation Therapy Versus Single-Fraction Radiosurgery for Brain MetastasesJairam V, Kann B, Patel K, Yu J, Hansen J, Husain Z, Bindra R, Contessa J, Omay S, Chiang V, Park H. Evolving National Practice Patterns of Hypofractionated Stereotactic Radiation Therapy Versus Single-Fraction Radiosurgery for Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e227. DOI: 10.1016/j.ijrobp.2018.07.775.
• Incidence of radiographically occult nodal metastases in HPV+ oropharyngeal carcinoma: Implications for reducing elective nodal coverageLoganadane G, Kelly JR, Lee NC, Kann BH, Mahajan A, Hansen JE, Belkacémi Y, Yarbrough W, Husain ZA. Incidence of radiographically occult nodal metastases in HPV+ oropharyngeal carcinoma: Implications for reducing elective nodal coverage. Practical Radiation Oncology 2018, 8: 397-403. PMID: 29730282, DOI: 10.1016/j.prro.2018.03.009.
• Re-engineering and evaluation of anti-DNA autoantibody 3E10 for therapeutic applicationsRattray Z, Dubljevic V, Rattray NJW, Greenwood DL, Johnson CH, Campbell JA, Hansen JE. Re-engineering and evaluation of anti-DNA autoantibody 3E10 for therapeutic applications. Biochemical And Biophysical Research Communications 2018, 496: 858-864. PMID: 29374508, DOI: 10.1016/j.bbrc.2018.01.139.
• Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus.Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, Yelin EH, Ginzler E, Hanly JG, Peschken C, Gordon C, Nived O, Aranow C, Bae SC, Isenberg D, Rahman A, Hansen JE, Pierre Y, Clarke AE. Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. The Journal Of Rheumatology 2018, 45: 393-396. PMID: 29335347, PMCID: PMC5834350, DOI: 10.3899/jrheum.170652.
• Metabolomics guided pathway analysis reveals link between cancer metastasis, cholesterol sulfate, and phospholipidsJohnson CH, Santidrian AF, LeBoeuf SE, Kurczy ME, Rattray NJW, Rattray Z, Warth B, Ritland M, Hoang LT, Loriot C, Higa J, Hansen JE, Felding BH, Siuzdak G. Metabolomics guided pathway analysis reveals link between cancer metastasis, cholesterol sulfate, and phospholipids. Cancer & Metabolism 2017, 5: 9. PMID: 29093815, PMCID: PMC5663111, DOI: 10.1186/s40170-017-0171-2.
• Environmental Influences in the Etiology of Colorectal Cancer: the Premise of MetabolomicsRattray NJW, Charkoftaki G, Rattray Z, Hansen JE, Vasiliou V, Johnson CH. Environmental Influences in the Etiology of Colorectal Cancer: the Premise of Metabolomics. Current Pharmacology Reports 2017, 3: 114-125. PMID: 28642837, PMCID: PMC5475285, DOI: 10.1007/s40495-017-0088-z.
• Breast cancer in systemic lupusBernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin P, Ginzler E, Romero-Diaz J, Peschken C, Jacobsen S, Hanly JG, Gordon C, Nived O, Yelin EH, Isenberg D, Rahman A, Bae SC, Joseph L, Witte T, Ruiz-Irastorza G, Aranow C, Kamen D, Sturfeldt G, Foulkes WD, Hansen JE, St Pierre Y, Raymer PC, Tessier-Cloutier B, Clarke AE. Breast cancer in systemic lupus. Lupus 2016, 26: 311-315. PMID: 27687028, PMCID: PMC5250552, DOI: 10.1177/0961203316664595.
• A lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumorsChen Z, Patel JM, Noble PW, Garcia C, Hong Z, Hansen JE, Zhou J. A lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors. Oncotarget 2016, 7: 59965-59975. PMID: 27494868, PMCID: PMC5312362, DOI: 10.18632/oncotarget.11015.
• DNA-damaging autoantibodies and cancer: the lupus butterfly theoryNoble PW, Bernatsky S, Clarke AE, Isenberg DA, Ramsey-Goldman R, Hansen JE. DNA-damaging autoantibodies and cancer: the lupus butterfly theory. Nature Reviews Rheumatology 2016, 12: 429-434. PMID: 27009542, DOI: 10.1038/nrrheum.2016.23.
• Chapter 46 Malignancies in Systemic Lupus ErythematosusTissera H, Clarke A, Goldman R, Gordon C, Hansen J, Bernatsky S. Chapter 46 Malignancies in Systemic Lupus Erythematosus. 2016, 411-415. DOI: 10.1016/b978-0-12-801917-7.00046-2.
• mRNA Expression of TP53 Attenuates Survival of HPV+ Locally Advanced Head and Neck CancerAneja S, Contessa J, Husain Z, Glazer P, Hansen J, Bindra R, Yu J. mRNA Expression of TP53 Attenuates Survival of HPV+ Locally Advanced Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e350-e351. DOI: 10.1016/j.ijrobp.2015.07.1440.
• Abstract 4276: Engineering a trivalent lupus anti-DNA autoantibody fragment for cancer therapyPatel J, Noble P, Chan G, Weisbart R, Hansen J. Abstract 4276: Engineering a trivalent lupus anti-DNA autoantibody fragment for cancer therapy. 2015, 4276-4276. DOI: 10.1158/1538-7445.am2015-4276.
• DNA-dependent targeting of cell nuclei by a lupus autoantibodyWeisbart RH, Chan G, Jordaan G, Noble PW, Liu Y, Glazer PM, Nishimura RN, Hansen JE. DNA-dependent targeting of cell nuclei by a lupus autoantibody. Scientific Reports 2015, 5: 12022. PMID: 26156563, PMCID: PMC4496662, DOI: 10.1038/srep12022.
• Optimizing a Lupus Autoantibody for Targeted Cancer TherapyNoble PW, Chan G, Young MR, Weisbart RH, Hansen JE. Optimizing a Lupus Autoantibody for Targeted Cancer Therapy. Cancer Research 2015, 75: 2285-2291. PMID: 25832653, DOI: 10.1158/0008-5472.can-14-2278.
• Abstract 654: Targeting K-ras mutant cancer cells with a lupus anti-guanosine antibodyYoung M, Noble P, Weisbart R, Hansen J. Abstract 654: Targeting K-ras mutant cancer cells with a lupus anti-guanosine antibody. 2014, 654-654. DOI: 10.1158/1538-7445.am2014-654.
• Abstract 4220: A cell-penetrating nucleolytic lupus autoantibody damages DNA and is toxic to BRCA2-deficient cancer cellsNoble P, Young M, Weisbart R, Hansen J. Abstract 4220: A cell-penetrating nucleolytic lupus autoantibody damages DNA and is toxic to BRCA2-deficient cancer cells. 2014, 4220-4220. DOI: 10.1158/1538-7445.am2014-4220.
• A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cellsNoble PW, Young MR, Bernatsky S, Weisbart RH, Hansen JE. A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells. Scientific Reports 2014, 4: 5958. PMID: 25091037, PMCID: PMC5380011, DOI: 10.1038/srep05958.
• Systemic Lupus Erythematosus and Malignancies A Review ArticleTessier-Cloutier B, Clarke AE, Ramsey-Goldman R, Gordon C, Hansen JE, Bernatsky S. Systemic Lupus Erythematosus and Malignancies A Review Article. Rheumatic Disease Clinics Of North America 2014, 40: 497-506. PMID: 25034158, DOI: 10.1016/j.rdc.2014.04.005.
• Breast Cancer in Systemic Lupus ErythematosusCloutier B, Clarke AE, Ramsey-Goldman R, Wang Y, Foulkes W, Gordon C, Hansen JE, Yelin E, Urowitz MB, Gladman D, Fortin PR, Wallace DJ, Petri M, Manzi S, Ginzler EM, Labrecque J, Edworthy S, Dooley MA, Senécal JL, Peschken CA, Bae SC, Isenberg D, Rahman A, Ruiz-Irastorza G, Hanly JG, Jacobsen S, Nived O, Witte T, Criswell LA, Barr SG, Dreyer L, Sturfelt G, Bernatsky S. Breast Cancer in Systemic Lupus Erythematosus. Oncology 2013, 85: 117-121. PMID: 23887245, PMCID: PMC3934367, DOI: 10.1159/000353138.
• Abstract 4319: Lupus antibody-based cancer therapy.Hansen J, Chan G, Liu Y, Hegan D, Dalal S, Dray E, Kwon Y, Xu Y, Xu X, Peterson-Roth E, Geiger E, Liu Y, Gera J, Sweasy J, Sung P, Rockwell S, Nishimura R, Weisbart R, Glazer P. Abstract 4319: Lupus antibody-based cancer therapy. Cancer Research 2013, 73: 4319-4319. DOI: 10.1158/1538-7445.am2013-4319.
• A Rare Cell-penetrating Anti-DNA Antibody Inhibits DNA Repair, Sensitizes Tumors To DNA-damaging Therapy, and is Synthetically Lethal to BRCA2-deficient Cancer CellsHansen J, Chan G, Liu Y, Gera J, Sweasy J, Sung P, Rockwell S, Nishimura R, Weisbart R, Glazer P. A Rare Cell-penetrating Anti-DNA Antibody Inhibits DNA Repair, Sensitizes Tumors To DNA-damaging Therapy, and is Synthetically Lethal to BRCA2-deficient Cancer Cells. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s163. DOI: 10.1016/j.ijrobp.2012.07.422.
• Targeting Cancer with a Lupus AutoantibodyHansen JE, Chan G, Liu Y, Hegan DC, Dalal S, Dray E, Kwon Y, Xu Y, Xu X, Peterson-Roth E, Geiger E, Liu Y, Gera J, Sweasy JB, Sung P, Rockwell S, Nishimura RN, Weisbart RH, Glazer PM. Targeting Cancer with a Lupus Autoantibody. Science Translational Medicine 2012, 4: 157ra142. PMID: 23100628, PMCID: PMC3713477, DOI: 10.1126/scitranslmed.3004385.
• A Cell-Penetrating Bispecific Antibody for Therapeutic Regulation of Intracellular TargetsWeisbart RH, Gera JF, Chan G, Hansen JE, Li E, Cloninger C, Levine AJ, Nishimura RN. A Cell-Penetrating Bispecific Antibody for Therapeutic Regulation of Intracellular Targets. Molecular Cancer Therapeutics 2012, 11: 2169-2173. PMID: 22863609, DOI: 10.1158/1535-7163.mct-12-0476-t.
• MicroRNA Profiling of Cutaneous T-cell Lymphoma Cell Lines: Implications for Pathophysiology and TherapyHansen J, Reza F, Nallur S, Lewis J, Carlson K, Lin W, Weidhaas J, Wilson L, Girardi M. MicroRNA Profiling of Cutaneous T-cell Lymphoma Cell Lines: Implications for Pathophysiology and Therapy. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s22. DOI: 10.1016/j.ijrobp.2011.06.045.
• Recombinant Fv-Hsp70 Protein Mediates Neuroprotection After Focal Cerebral Ischemia in RatsZhan X, Ander BP, Liao IH, Hansen JE, Kim C, Clements D, Weisbart RH, Nishimura RN, Sharp FR. Recombinant Fv-Hsp70 Protein Mediates Neuroprotection After Focal Cerebral Ischemia in Rats. Stroke 2010, 41: 538-543. PMID: 20075343, PMCID: PMC2957177, DOI: 10.1161/strokeaha.109.572537.
• Antibody-mediated FOXP3 protein therapy induces apoptosis in cancer cells in vitro and inhibits metastasis in vivo.Heinze E, Baldwin S, Chan G, Hansen J, Song J, Clements D, Aragon R, Nishimura R, Reeves M, Weisbart R. Antibody-mediated FOXP3 protein therapy induces apoptosis in cancer cells in vitro and inhibits metastasis in vivo. International Journal Of Oncology 2009, 35: 167-73. PMID: 19513564, DOI: 10.3892/ijo_00000325.
• p21-activated Kinase-aberrant Activation and Translocation in Alzheimer Disease Pathogenesis*Ma QL, Yang F, Calon F, Ubeda OJ, Hansen JE, Weisbart RH, Beech W, Frautschy SA, Cole GM. p21-activated Kinase-aberrant Activation and Translocation in Alzheimer Disease Pathogenesis*. Journal Of Biological Chemistry 2008, 283: 14132-14143. PMID: 18347024, PMCID: PMC2376243, DOI: 10.1074/jbc.m708034200.
• Intranuclear Protein Transduction through a Nucleoside Salvage Pathway*Hansen JE, Tse CM, Chan G, Heinze ER, Nishimura RN, Weisbart RH. Intranuclear Protein Transduction through a Nucleoside Salvage Pathway*. Journal Of Biological Chemistry 2007, 282: 20790-20793. PMID: 17525162, DOI: 10.1074/jbc.c700090200.
• Antibody-Mediated p53 Protein Therapy Prevents Liver Metastasis In vivoHansen JE, Fischer LK, Chan G, Chang SS, Baldwin SW, Aragon RJ, Carter JJ, Lilly M, Nishimura RN, Weisbart RH, Reeves ME. Antibody-Mediated p53 Protein Therapy Prevents Liver Metastasis In vivo. Cancer Research 2007, 67: 1769-1774. PMID: 17308119, DOI: 10.1158/0008-5472.can-06-3783.
• ANTIBODY‐MEDIATED P53 PROTEIN THERAPY PREVENTS LIVER METASTASIS IN VIVO.: 98Hansen J, Fischer L, Nishimura R, Chan G, Chang S, Baldwin S, Aragon R, Carter J, Lilly M, Weisbart R, Reeves M. ANTIBODY‐MEDIATED P53 PROTEIN THERAPY PREVENTS LIVER METASTASIS IN VIVO.: 98. Journal Of Investigative Medicine 2007, 55: s92. DOI: 10.1097/00042871-200701010-00106.
• Antibody-mediated Hsp70 protein therapyHansen JE, Sohn W, Kim C, Chang SS, Huang NC, Santos DG, Chan G, Weisbart RH, Nishimura RN. Antibody-mediated Hsp70 protein therapy. Brain Research 2006, 1088: 187-196. PMID: 16630585, DOI: 10.1016/j.brainres.2006.03.025.
• Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer diseaseZhao L, Ma QL, Calon F, Harris-White ME, Yang F, Lim GP, Morihara T, Ubeda OJ, Ambegaokar S, Hansen JE, Weisbart RH, Teter B, Frautschy SA, Cole GM. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nature Neuroscience 2006, 9: 234-242. PMID: 16415866, DOI: 10.1038/nn1630.
• Antibody Mediated Transduction of Therapeutic Proteins into Living CellsHansen JE, Weisbart RH, Nishimura RN. Antibody Mediated Transduction of Therapeutic Proteins into Living Cells. The Scientific World JOURNAL 2005, 5: 782-788. PMID: 16170440, PMCID: PMC5936519, DOI: 10.1100/tsw.2005.98.
• An intracellular delivery vehicle for protein transduction of micro-dystrophinWeisbart RH, Hansen JE, Nishimura RN, Chan G, Wakelin R, Chang SS, Baresi L, Chamberlain JS. An intracellular delivery vehicle for protein transduction of micro-dystrophin. Journal Of Drug Targeting 2005, 13: 81-87. PMID: 15823959, DOI: 10.1080/10611860400029002.
• Development of a Lupus Anti-Dna Antibody as An Intracellular Delivery Vehicle for Protein Transduction of Micro-DystrophinWeisbart R, Chan G, Wakelin R, Nishimura R, Hansen J, Chang S, Baresi L, Chamberlain J. Development of a Lupus Anti-Dna Antibody as An Intracellular Delivery Vehicle for Protein Transduction of Micro-Dystrophin. Journal Of Investigative Medicine 2005, 53: 129-129. DOI: 10.1177/1081558905053001283.
• Antibody-mediated transduction of p53 selectively kills cancer cells.Weisbart RH, Hansen JE, Chan G, Wakelin R, Chang SS, Heinze E, Miller CW, Koeffler PH, Yang F, Cole GM, Min YS, Nishimura RN. Antibody-mediated transduction of p53 selectively kills cancer cells. International Journal Of Oncology 2004, 25: 1867-73. PMID: 15547728, DOI: 10.3892/ijo.25.6.1867.